Home
HomeChat
Markets
AlertsCalendarScreenerCharts
Portfolio
WatchlistsPortfolioFiles
Account
Docs
Sign upJoinLog inLogin

Novo Nordisk A/S (NVO) stock profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity and with Valo Health, Inc. to discover and develop novel drug programs for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Key facts

SymbolNVO
ExchangeNYSE
SectorHealthcare
IndustryDrug Manufacturers - General
CEOMaziar Mike Doustdar
Employees77406
HeadquartersBagsvaerd, DK
IPO1981-04-30
Websitewww.novonordisk.com

Explore NVO on Vantafin

  • Novo Nordisk A/S Overview
  • Novo Nordisk A/S Financials
  • Novo Nordisk A/S News
  • Novo Nordisk A/S Events
  • Novo Nordisk A/S SEC filings
  • Novo Nordisk A/S Transcripts

Frequently asked questions

What does Novo Nordisk A/S (NVO) do?
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity and with Valo Health, Inc. to discover and develop novel drug programs for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Where is NVO stock listed?
Novo Nordisk A/S trades under the ticker NVO on NYSE.
How can I research NVO's financials and filings?
Vantafin provides Novo Nordisk A/S's income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the NVO profile.